ArticleCell reports. Medicine2021
Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Chorus line in oral squamous cell carcinoma: How stromal and immune players orchestrate tumor progression (Review).International journal of molecular medicine · 2026Review
- Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Regulatory T cells in cancer anti-PD-(L)1 therapy.Human cell · 2025Review
- Immune Microenvironment in Oral Potentially Malignant Disorders and Oral Cancer: A Narrative Review.International journal of molecular sciences · 2025Review
- Heterogeneity analysis and prognostic model construction of HPV negative oral squamous cell carcinoma T cells using ScRNA-seq and bulk-RNA analysis.Functional & integrative genomics · 2025Article
- Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation.Frontiers in immunology · 2025Review
- Unveiling the power of Treg.Sig: a novel machine-learning derived signature for predicting ICI response in melanoma.Frontiers in immunology · 2025Article
- PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery.Journal of chemical information and modeling · 2024Article
- 4-nitroquinoline 1-oxide-induced oral epithelial lesions exhibit time- and stage-dependent changes in the tumor immune microenvironment.Frontiers in oncology · 2024Article
- The Three-Dimensional In Vitro Cell Culture Models in the Study of Oral Cancer Immune Microenvironment.Cancers · 2023Review
- The Role of IL-17 in the Pathogenesis of Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
- Targeting oral tumor microenvironment for effective therapy.Cancer cell international · 2023Review
- AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor.Chemical science · 2023Article
- The impact ofJournal of Cancer · 2023Article
- Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma.Immunity, inflammation and disease · 2022Article
- Identification of a novel autophagy-related prognostic signature and small molecule drugs for glioblastoma by bioinformatics.BMC medical genomics · 2022Article
- Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers.Frontiers in immunology · 2022Review
- Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.Frontiers in oral health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Immune suppression by CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.